60
Participants
Start Date
June 14, 2022
Primary Completion Date
June 30, 2026
Study Completion Date
August 30, 2027
Atezolizumab
Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by investigators.
Beijing Tiantan Hospital,Capital Medical University, Beijing
Beijing Chest Hospital, Beijing
The First Affiliated Hospital Of Jinzhou Medical University, Jinzhou
Shanghai Chest Hospital, Shanghai
Nanjing Chest Hospital, Nanjing
Jiangsu Cancer Hospital, Nanjing
Changzhou First People's Hospital, Changzhou
Anhui Province Cancer Hospital, Hefei
The First Affiliated Hospital of Anhui Medical University, Hefei
Linyishi Cancer Hospital, Linyi
Tianjin Medical University General Hospital, Tianjin
Tianjin Cancer Hospital, Tianjin
The Second Affiliated Hospital, Zhejiang University, Hangzhou
Sir Run Run Shaw Hospital Zhejiang University, Hangzhou
Fujian Cancer Hospital, Fuzhou
The First Affiliated Hospital of Xiamen University, Xiamen
Daping Hospital of Third Military Medical University, Chongqing
The Third Xiangya Hospital Of Central South University, Changsha
Tumor Center,Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
Renmin Hospital of Wuhan University, Wuhan
Cancer Hospital of Shantou University Medical College, Shantou
Hoffmann-La Roche
INDUSTRY